BRCA1 and ovarian cancer: Economic evaluations of genetic applications recognize three categories of BRCA1/2 genetic testing programs as cost-effective: (i) population-based screening among Ashkenazi Jews; (ii) family history-based screening, although methods on how to select high-risk women from the general population and the related cost are not detailed in literature studies; and (iii) cancer-based genetic screening, which includes tools for the identification of affected women at higher risk of inherited breast and ovarian cancers (D'Andrea et al., 2016).